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Phosphatidylserine (PS) is an upstream immune check-
point that drives global immunosuppression. Previous
work has shown that PS targeting agents can override
PS-driven immunosuppression and re-program the
tumor microenvironment from immunosuppressive to
immunosupportive, break tumor immune tolerance, and
elicit potent de novo antitumor T-cell immunity. In the
present study, the antitumor effect of the combination
of a PS-targeting antibody with antibodies that inhibit
the downstream immune checkpoints PD-1 or CTLA-4
antibody in the K1735 mouse melanoma model was
examined. Tumor-bearing mice were treated with each
antibody alone or the combination at 5 to 10 mg/kg,
twice a week. Combination therapy potently suppressed
tumor growth and improved overall survival compared
to single agent treatment. Flow cytometry revealed that
combination therapy induced the highest ratio of
tumor-infiltrating immune effector to suppressor cells.
Importantly, combination treatment also significantly
decreased the levels of myeloid-derived suppressor cells
(MDSC) in the spleen. In addition, inhibition of PS and
PD-1 or CTLA-4 resulted in significantly more IL-2 and
IFNg-secreting splenic CD4+ and CD8+ T cells than any
single agent treatment. Finally, combined immune check-
point blockade did not induce any observable toxicity
following multiple treatment doses. In summary, our find-
ings demonstrate that the combination of antibody-
mediated PS blockade with an inhibition of established
immune checkpoints (e.g., PD-1 and CTLA-4) represents
a promising strategy for cancer immunotherapy.
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